Medical treatment of neuroendocrine neoplasms

Wouter W. de Herder; Richard A. Feelders; Johannes Hofland

doi:10.1016/j.coemr.2021.03.019

Medical treatment of neuroendocrine neoplasms

Wouter W. de Herder^*
, Richard A. Feelders
, Johannes Hofland

^*Corresponding author for this work

Internal Medicine

Research output: Contribution to journal › Review article › Academic › peer-review

3 Citations (Scopus)

77 Downloads (Pure)

Abstract

Medical therapy of clinically nonfunctioning (nonsecreting) low grade (grade 1–2) neuroendocrine neoplasms consists of first-line first generation somatostatin analogs and second-line or third-line peptide receptor radiotherapy with radiolabeled beta-emitting somatostatin analogs, Everolimus, Sunitinib, and interferon-α. Second-generation somatostatin analogs like Pasireotide have no proven superiority over first-generation somatostatin analogs. Chemotherapy is usually reserved as second-line therapy in pancreatic neuroendocrine neoplasms and neuroendocrine carcinomas.

Original language	English
Pages (from-to)	139-144
Number of pages	6
Journal	Current Opinion in Endocrine and Metabolic Research
Volume	18
DOIs	https://doi.org/10.1016/j.coemr.2021.03.019
Publication status	Published - Jun 2021

Bibliographical note

Funding Information:
WWH received speaker fees from Novartis – AAA, Ipsen and Pfizer and research support from Ipsen .

Publisher Copyright:
© 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.coemr.2021.03.019Licence: CC BY

Medical treatment of neuroendocrine neoplasmsFinal published version, 277 KBLicence: CC BY

Cite this

@article{801db7c285de4065b839e1fb37723c99,

title = "Medical treatment of neuroendocrine neoplasms",

abstract = "Medical therapy of clinically nonfunctioning (nonsecreting) low grade (grade 1{\textendash}2) neuroendocrine neoplasms consists of first-line first generation somatostatin analogs and second-line or third-line peptide receptor radiotherapy with radiolabeled beta-emitting somatostatin analogs, Everolimus, Sunitinib, and interferon-α. Second-generation somatostatin analogs like Pasireotide have no proven superiority over first-generation somatostatin analogs. Chemotherapy is usually reserved as second-line therapy in pancreatic neuroendocrine neoplasms and neuroendocrine carcinomas.",

author = "\{de Herder\}, \{Wouter W.\} and Feelders, \{Richard A.\} and Johannes Hofland",

note = "Funding Information: WWH received speaker fees from Novartis {\textendash} AAA, Ipsen and Pfizer and research support from Ipsen . Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = jun,

doi = "10.1016/j.coemr.2021.03.019",

language = "English",

volume = "18",

pages = "139--144",

journal = "Current Opinion in Endocrine and Metabolic Research",

issn = "2451-9650",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Medical treatment of neuroendocrine neoplasms

AU - de Herder, Wouter W.

AU - Feelders, Richard A.

AU - Hofland, Johannes

PY - 2021/6

Y1 - 2021/6

N2 - Medical therapy of clinically nonfunctioning (nonsecreting) low grade (grade 1–2) neuroendocrine neoplasms consists of first-line first generation somatostatin analogs and second-line or third-line peptide receptor radiotherapy with radiolabeled beta-emitting somatostatin analogs, Everolimus, Sunitinib, and interferon-α. Second-generation somatostatin analogs like Pasireotide have no proven superiority over first-generation somatostatin analogs. Chemotherapy is usually reserved as second-line therapy in pancreatic neuroendocrine neoplasms and neuroendocrine carcinomas.

AB - Medical therapy of clinically nonfunctioning (nonsecreting) low grade (grade 1–2) neuroendocrine neoplasms consists of first-line first generation somatostatin analogs and second-line or third-line peptide receptor radiotherapy with radiolabeled beta-emitting somatostatin analogs, Everolimus, Sunitinib, and interferon-α. Second-generation somatostatin analogs like Pasireotide have no proven superiority over first-generation somatostatin analogs. Chemotherapy is usually reserved as second-line therapy in pancreatic neuroendocrine neoplasms and neuroendocrine carcinomas.

UR - https://www.scopus.com/pages/publications/85105008953

U2 - 10.1016/j.coemr.2021.03.019

DO - 10.1016/j.coemr.2021.03.019

M3 - Review article

AN - SCOPUS:85105008953

SN - 2451-9650

VL - 18

SP - 139

EP - 144

JO - Current Opinion in Endocrine and Metabolic Research

JF - Current Opinion in Endocrine and Metabolic Research

ER -

Medical treatment of neuroendocrine neoplasms

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this